HMMR and leukemia: Interestingly, the authors documented that the addition of nivolumab to CTL cultures for several days increased both specific T-cell responses against various leukemia-associated antigens, mainly PRAME, RHAMM and WT1, as well as T cell cytotoxic effects against primary AML blasts [31–33].